JP2024500250A5 - - Google Patents

Info

Publication number
JP2024500250A5
JP2024500250A5 JP2023560254A JP2023560254A JP2024500250A5 JP 2024500250 A5 JP2024500250 A5 JP 2024500250A5 JP 2023560254 A JP2023560254 A JP 2023560254A JP 2023560254 A JP2023560254 A JP 2023560254A JP 2024500250 A5 JP2024500250 A5 JP 2024500250A5
Authority
JP
Japan
Prior art keywords
protein
dsg2
domain
isolated polypeptide
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500250A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/063433 external-priority patent/WO2022132854A1/en
Publication of JP2024500250A publication Critical patent/JP2024500250A/ja
Publication of JP2024500250A5 publication Critical patent/JP2024500250A5/ja
Pending legal-status Critical Current

Links

JP2023560254A 2020-12-15 2021-12-15 Covid-19の治療のためのdsg2組成物及び方法 Pending JP2024500250A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US63/125,583 2020-12-15
US202163274715P 2021-11-02 2021-11-02
US63/274,715 2021-11-02
PCT/US2021/063433 WO2022132854A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Publications (2)

Publication Number Publication Date
JP2024500250A JP2024500250A (ja) 2024-01-05
JP2024500250A5 true JP2024500250A5 (https=) 2024-11-29

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560254A Pending JP2024500250A (ja) 2020-12-15 2021-12-15 Covid-19の治療のためのdsg2組成物及び方法

Country Status (9)

Country Link
EP (1) EP4263588A1 (https=)
JP (1) JP2024500250A (https=)
KR (1) KR20230120141A (https=)
AU (1) AU2021400845A1 (https=)
CA (1) CA3202364A1 (https=)
IL (1) IL303444A (https=)
MX (1) MX2023006704A (https=)
TW (1) TW202237634A (https=)
WO (1) WO2022132854A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005327A (es) * 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.
CN116458893A (zh) * 2023-04-19 2023-07-21 电子科技大学 一种covid-19后心肌缺血的早期筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy

Similar Documents

Publication Publication Date Title
Ko et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
US12497462B2 (en) Anti-CD26 proteins and uses thereof
CA2833785C (en) Compositions and methods for the treatment of neuromyelitis optica
JP6954842B2 (ja) 増強された活性を有する抗体及びその改変方法
SI2802606T1 (en) Improves the transfer of healing molecules through the hematoencephalic barrier
BR112019016104A2 (pt) composição farmacêutica de baixo ph compreendendo construtos de anticorpo que empregam células t
US20230293647A1 (en) Polypeptide
CN110662768A (zh) 治疗性抗cd40配体抗体
CA2824805A1 (en) Il-27 antagonists for treating inflammatory diseases
WO2021047559A1 (zh) 一种断裂型内含肽、使用其的重组多肽的制备方法
JP2024500250A5 (https=)
CA3052903A1 (en) Anti human annexin a1 antibody
JP2020536495A (ja) 抗lag−3抗体及びその使用
CA3134224A1 (en) Composition for preventing or treating brain and nervous system disease
JP2022549172A5 (https=)
CN104114187A (zh) 去糖基化的人类抗体、其融合蛋白质及用途
WO2021148884A1 (en) Anti-wuhan coronavirus antibodies
EP3288974A2 (en) Type iii secretion system targeting molecules
JP2021518132A5 (https=)
JP2025515304A (ja) Siglec-8結合タンパク質及びその使用方法
JP2025506341A5 (https=)
JP2024540220A5 (https=)
JP2021526833A5 (https=)
CN115702169A (zh) 包含促红细胞生成素多肽的融合蛋白
US20240327541A1 (en) Methods and compositions comprising novel bispecific antibodies